ersodetug — Topline data
H2 2026
Topline results for the fully enrolled open-label study are expected in the second half of 2026Source filing
RZLT biotech catalysts & pipeline
REZOLUTE INC · Data as of 2026-09-08
Upcoming catalysts
ersodetug — Regulatory decision
H2 2026
Our priorities for the second half of 2026 are to: (i) achieve alignment with the U.S. Food and Drug Administration ("FDA") on the path forward in congenital HI following the completion of the sunRIZE study and (ii) complete enrollment and announce topline data for the registrational Phase 3 upLIFT study.Source filing